Form 4 Filing for CRISPR Therapeutics AG

This SEC filing details transactions made by KASINGER JAMES R., General Counsel and Secretary of CRISPR Therapeutics AG. On October 13, 2026, 2113 Restricted Stock Units vested, with the underlying 2113 Common Shares being disposed of to cover tax withholding obligations, as per the company's RSU Settlement Policy. This transaction resulted in 0 shares held post-transaction for the RSUs. Concurrently, 2113 Common Shares were acquired, leading to a post-transaction holding of 96897 shares. On October 14, 2026, 1040 Common Shares were disposed of at a price of $49.26 per share, resulting in a post-transaction holding of 95857 shares. The RSU award was granted on October 13, 2023, with vesting occurring in thirds on October 13, 2024, 2025, and 2026.